EUVIMEDEUVIMED entdecken
Crossref

Structure-Guided Design of Potent and Selective Covalent Inhibitors Targeting the SARS-CoV-2 Papain-like Protease

Mona Sharafi, Wei Pin Teh iD, Jeremy Green, Paul S Charifson, Jinhua Wang, Orville A Pemberton, Amanda M Nevins, Ming Lye, Xiaoxi Liu, Anthony C Varca, Callum D Owen iD, Kimberley Morsheimer iD und 13 weitere

Journal of Medicinal Chemistry · 12.02.2026 · 69 (3) · 2197-2214

DOI: 10.1021/acs.jmedchem.5c01973 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 20.01.2026. Verfasst von Mona Sharafi und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States. Hauptthemen laut MEDLINE: Antiviral Agents, SARS-CoV-2, Coronavirus Papain-Like Proteases, COVID-19 Drug Treatment. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Boston University, AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COVID-19 pandemic led to numerous initiatives to create antiviral medications and vaccines for the treatment and prevention of infections. However, the need remains for new therapies with distinct mechanisms of action from current treatment of COVID-19 infections as well as for future pandemic preparedness. SARS-CoV-2 papain-like protease (PLpro) is a cysteine protease that cleaves the viral polyprotein and possesses deubiquitylase (DUB) and deISGylase activity that can act on host proteins. Here, we report the structure-guided development of covalent inhibitors of SARS-CoV-2 PLpro that possess low nanomolar to subnanomolar antiviral activity in cell assays and inhibit viral replication in a mouse model of SARS-CoV-2 infection. The most potent inhibitors contain N-propargylamide electrophiles, a relatively inert warhead not typically featured in covalent protease inhibitors. These findings provide a foundation for further discovery and optimization of covalent PLpro inhibitors that could lead to future antiviral therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsSARS-CoV-2Coronavirus Papain-Like ProteasesCOVID-19 Drug TreatmentProtease InhibitorsCysteine Proteinase InhibitorsAnimalsHumansDrug DesignMiceStructure-Activity RelationshipVirus ReplicationCOVID-19

Substanzen

Antiviral AgentsCoronavirus Papain-Like Proteasespapain-like protease, SARS-CoV-2Protease InhibitorsCysteine Proteinase Inhibitors

Autor:innen und Institutionen

  • Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.
  • Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts 02115, United States.
  • Drug Discovery Sciences Core, Blavatinik Institute, Harvard Medical School, Boston, Massachusetts 02115, United States.
  • Research and Development, AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States.
  • National Emerging Infectious Diseases Laboratories, Department of Virology, Immunology, and Microbiology, Chobanian and Avedisian School of Medicine, Boston University, Boston, Massachusetts 02118, United States.
  • National Emerging Infectious Diseases Laboratories, Department of Biochemistry and Cell Biology, Chobanian and Avedisian School of Medicine, Boston University, Boston, Massachusetts 02118, United States.

ORCID-Profile: Wei Pin Teh, Callum D Owen, Kimberley Morsheimer, Alan Wacquiez, Jennifer Smith, Jarrod A Marto, Rob A Davey, Mark N Namchuk, Sara J Buhrlage

Förderung

  • Boston University
  • AbbVie

Zitieren

APA

Sharafi, M., Teh, W. P., Green, J., Charifson, P. S., Wang, J., Pemberton, O. A., Nevins, A. M., Lye, M., Liu, X., Varca, A. C., Owen, C. D., Morsheimer, K., Wacquiez, A., Dawson, C., Steuber, C., Smith, J., Girardi, N. M., Magin, R. S., Marto, J. A., …, & Buhrlage, S. J. (2026). Structure-Guided Design of Potent and Selective Covalent Inhibitors Targeting the SARS-CoV-2 Papain-like Protease. Journal of Medicinal Chemistry, 69(3), 2197-2214. https://doi.org/10.1021/acs.jmedchem.5c01973

Vancouver

Sharafi M, Teh WP, Green J, Charifson PS, Wang J, Pemberton OA, et al. Structure-Guided Design of Potent and Selective Covalent Inhibitors Targeting the SARS-CoV-2 Papain-like Protease. Journal of Medicinal Chemistry. 2026;69(3):2197-2214. doi:10.1021/acs.jmedchem.5c01973

BibTeX
@article{Sharafi2026,
  author = {Sharafi, Mona and Teh, Wei Pin and Green, Jeremy and Charifson, Paul S and Wang, Jinhua and Pemberton, Orville A and Nevins, Amanda M and Lye, Ming and Liu, Xiaoxi and Varca, Anthony C and Owen, Callum D and Morsheimer, Kimberley and Wacquiez, Alan and Dawson, Christpher and Steuber, Christopher and Smith, Jennifer and Girardi, Nicholas M and Magin, Robert S and Marto, Jarrod A and Saeed, Mohsan and Davey, Rob A and Hardee, David and Ng, Teresa I and Namchuk, Mark N and Buhrlage, Sara J},
  title = {Structure-Guided Design of Potent and Selective Covalent Inhibitors Targeting the SARS-CoV-2 Papain-like Protease},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {3},
  pages = {2197--2214},
  doi = {10.1021/acs.jmedchem.5c01973}
}
Kostenlos starten →